



CHRONIC AND ACUTE-ON-CHRONIC LIVER FAILURE

Clinical and translational research



EUROPEAN, NATIONAL AND LOCAL RESEARCH PROJECTS



Partner of the EF-CLIF



AN EUROPEAN NETWORK FOR THE STUDY OF CHRONIC LIVER FAILURE (CLIF) (www.efclif.com)


TO DEFINE ACLF (2013)

CLIF Acute-oN-ChrONic Liver Failure in Cirrhosis (CANONIC)

1343 patients with cirrhosis enrolled in 29 European centers

110 patients enrolled by AOSP-UNIBO

29 published articles



← 2° recruiting center in Europe →

TO PREDICT ACLF (2019)

Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT)

1308 patients with cirrhosis enrolled in 49 European centers

111 patients enrolled by AOSP-UNIBO

Evaluation of clinical data still ongoing

HORIZON 2020

CARBALIVE

Clinical evaluation of nanoporous carbon adsorbent with tailored porosity (Yaq-001) as a new therapy for the treatment of liver cirrhosis and non-alcoholic fatty liver disease (CARBALIVE)

GRANT AGREEMENT 634579

PI: Prof. Paolo Caraceni

ROLE IN THE PROJECT:
WP Leader of the Phase III clinical trial PREVENT-ACLF (WP6)

May 2015-Jun 2020

LIVERHOPE

Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis (LIVERHOPE)

GRANT AGREEMENT 731875

PI: Prof. Paolo Caraceni

ROLE IN THE PROJECT:
partner of the two clinical trials: Phase II (WP2) and phase III (WP3)

Jan 2017-Dec 2021

DECISION

Decompensated cirrhosis: identification of new combinatorial therapies based on systems approaches (DECISION)

GRANT AGREEMENT 847949

PI: Prof. Paolo Caraceni

ROLE IN THE PROJECT:
WP Leader of the proof-of-concept clinical trial (WP5)

Apr 2020-Sept 2025

ALIVER

Development of DIALIVE, a novel liver dialysis device for the treatment of patients with acute-on-chronic liver failure (ALIVER)

GRANT AGREEMENT 733057

PI: Prof. Paolo Caraceni

ROLE IN THE PROJECT:
third party of EF-CLIF consortium phase III clinical trial

Jan 2017-Dec 2021

Funded by Bando Ricerca Indipendente



Endorsed by



The use of human AlbumiN for the treatment of aScites in patients With hEpatic ciRrhosis: a multicenter, open-label randomized clinical trial (NCT01288794)



Coordinating center

POLICLINICO DI SANT'ORSOLA

THE LANCET www.thelancet.com Vol 391 June 16, 2018

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Paolo Caraceni, Oliviero Riggio, Paolo Angeli, Carlo Alessandria, Sergio Neri, Francesco G Foschi, Fabio Levantesi, Aldo Airolli, Sergio Boccia, Gianluca Svegliati-Baroni, Stefano Fagioli, Roberto G Romanelli, Raffaele Cozzolongo, Vito Di Marco, Vincenzo Sangiovanni, Filomena Morisco, Pierluigi Taniutto, Annalisa Tortora, Rosanna De Marco, Mario Angelico, Irene Cacciola, Gianfranco Elia, Alessandro Federico, Sara Massironi, Riccardo Guarisco, Alessandra Galioto, Giorgio Ballardini, Maria Rendina, Silvia Nardelli, Salvatore Piano, Chiara Elia, Loredana Prestianni, Federica Mirici Cappa, Lucia Cesarini, Loredana Simone, Chiara Pasquale, Marta Cavallin, Alida Andrealli, Federica Fidone, Matteo Ruggeri, Andrea Roncadori, Maurizio Baldassarre, Manuel Tufoni, Giacomo Zaccherini, Mauro Bernardi, for the ANSWER Study Investigators*



DATABASE MANAGEMENT
AND STATISTICAL ANALYSIS



PHARMACOECONOMIC
ANALYSIS



ANCILLARY TRANSLATIONAL
STUDIES